Oxcia is pleased to announce that the patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has now also been approved in Canada. Canada is a key market. Like other IPF markets it is displaying good growth, driven by an ageing population, improved clinical recognition and higher and earlier diagnostic rates. The patent is already approved in the US, Japan and China. The patent application is pending in Europe (EPO – European Patent Organization). The patent is valid until March 2039.
As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early 2023 a grant of 2.5 million euros within the EIC-Transition program. The pre-clinical program for OXC-201 is under completion and the first in human clinical Phase 1 trial is due to start in the beginning of 2027.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com